Navigation Links
CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
Date:1/5/2011

WOBURN, Mass., Jan. 5, 2011 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST® - Duke's Mouthwash and FIRST® - Mary's Mouthwash compounding kits. These products complete the FIRST® Magic Mouthwash line for CutisPharma. The product line already includes FIRST® - Mouthwash BLM, and FIRST® - BXN Mouthwash.  The active ingredients in FIRST® - Duke's Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, hydrocortisone, and nystatin. The active ingredients in FIRST® - Mary's Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, hydrocortisone, nystatin, and tetracycline. The kits are made for one patient and include pre-weighed powders, and a pre-measured suspension. With FIRST® - Mouthwash Kits, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.

"By launching FIRST® - Duke's and Mary's, physicians now have four of the more commonly prescribed magic mouthwash prescriptions available in a kit," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc.  "The Company now offers an expanded line of Magic Mouthwash formulations for patients, physicians, and pharmacists."

FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction.  Using FIRST® Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way.  A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has twelve proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and four Magic Mouthwash kits.  Several more compounding kits are in the planning stages.  FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need.  About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.  

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST®  Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding
2. CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators
3. Beaumont Hospital Launches Study of Single-Dose Radiation Treatment for Prostate Cancer
4. UBM Canon Launches Medical Manufacturing Events in India and Brazil
5. Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
6. Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test
7. CareFusion Launches Respiratory Airway Adapter to Improve Patient Safety and Reduce Hospital Costs
8. UBM TechInsights Launches Product Teardowns for Medical Electronics
9. Purdue Pharma L.P. Re-launches Partners Against Pain Website
10. CareFusion Launches Next-Generation Clinical Pulmonary and Cardiopulmonary Diagnostics Software
11. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
Breaking Medicine Technology:
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ODH, Inc.™ ... Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s ... PerformCARE to use behavioral health analytics to improve Medicaid population health management. , ODH ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
Breaking Medicine News(10 mins):